Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 30, 2007
Business Overview: The Company operates two segments: Implantable Medical Components (IMC), manufacturing batteries and components for pacemakers and defibrillators, and Electrochem Commercial Power (ECP), producing high-performance batteries for oil & gas, military, and aerospace applications.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2007 | Q1 2006 |
|---|---|---|
| Sales | $76,860 | $68,107 |
| Operating Income | $10,606 | $10,052 |
| Net Income | $10,669 | $6,650 |
| Diluted EPS | $0.43 | $0.28 |
| Operating Margin | 13.8% | 14.8% |
| Net Margin | 13.9% | 9.8% |
| Cash & Cash Equivalents | $147,128 | $38,888 |
| Short-term Investments | $78,614 | $71,416 |
| Total Debt (Convertible Notes) | $240,111 | $170,000 |
| Working Capital | $274,740 | $199,051 |
| Current Ratio | 6.3:1 | 5.7:1 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 13% to $76.9 million. IMC sales rose 13% driven by a 139% surge in ICD capacitor sales (partially due to customer inventory replenishment and supply issues) and 13% growth in feedthroughs. ECP sales grew 11% due to strong oil & gas and military demand.
- Profitability: Net income increased 60% to $10.7 million. Diluted EPS rose 54% to $0.43. This growth includes a one-time pre-tax gain of $4.5 million ($0.11 per diluted share) from the extinguishment of debt.
- Debt Restructuring: The Company exchanged $117.8 million of existing convertible notes (CSN I) for new notes (CSN II) and issued an additional $80 million of new notes. This eliminated a 2010 call/put option and resulted in the aforementioned gain on extinguishment.
- Liquidity: Cash and cash equivalents more than tripled to $147.1 million, primarily due to $76.0 million in net proceeds from the new debt issuance. Operating cash flow turned positive at $8.6 million compared to a $3.6 million outflow in the prior year.
- Cost Structure: Cost of sales as a percentage of sales increased to 62.8% from 59.4%, attributed to lower production volumes of ICD batteries (absorbing fixed costs) and a product mix shift toward lower-margin capacitors.
Guidance, Outlook, and Risks
- Acquisitions: Subsequent to the quarter, the Company acquired BIOMEC, Inc. for $11.4 million and announced a definitive agreement to acquire Enpath Medical, Inc. for approximately $102 million. These are expected to close in Q2 2007 and will be funded by existing cash.
- Capital Expenditures: The Company expects 2007 capital spending to range between $35.0 million and $45.0 million, with $20.0 million allocated to a new 80,000 sq. ft. ECP manufacturing facility in Massachusetts, expected to complete in mid-2008.
- Restructuring: Ongoing consolidation efforts (Carson City, Columbia, and Tijuana facilities) are expected to yield annual cost savings of $7.5 million to $9.1 million upon completion. The Carson City facility closure is scheduled for June 2007.
- Risks: Key risks include dependence on a limited number of customers (top three accounted for 69% of sales), integration challenges with Enpath, potential delays in facility consolidations, and regulatory changes in the healthcare industry.
- Tax Matters: The Company adopted FIN 48 regarding uncertainty in income taxes. While no adjustment was made to unrecognized tax benefits ($1.8 million) upon adoption, the balance could change significantly within 12 months due to audit settlements.
Investor Verification Checklist
- Debt Extinguishment Gain: Verify the sustainability of earnings by excluding the $4.5 million one-time gain on debt exchange from core operating performance.
- Customer Concentration: Assess the risk associated with the top three customers (Boston Scientific, Medtronic, St. Jude Medical) representing 69% of total sales.
- Acquisition Integration: Monitor the progress and financial impact of the Enpath Medical acquisition ($102 million) and BIOMEC acquisition ($11.4 million) announced post-quarter.
- Inventory Replenishment: Determine if the 139% spike in ICD capacitor sales is a one-time inventory restocking event or indicative of sustained demand growth.
- Restructuring Costs: Track remaining costs for facility consolidations (Carson City, Columbia, Tijuana) to ensure they remain within the estimated ranges of $7.7M-$7.9M and $8.4M-$8.9M respectively.